NICE Backs Teva’s Migraine Treatment Ajovy

March 23, 2020

The U.K.’s National Institute for Health and Care Excellence has recommended Teva’s Ajovy (fremanezumab) for preventing chronic migraine in adults where at least three previous preventive treatments have failed.

The recommendation was made based on clinical trial evidence showing that Ajovy works better than the best supporting care for preventing chronic migraine in people who have already tried three preventive treatments.

NICE says that the decision opens the treatment up to 10,000 patients via the National Health Service. The recommendation also included patients with chronic migraine for whom botulinum toxin type A failed, as clinical evidence showed that Ajovy may be beneficial for the population.

View today's stories